More than 400 people set to benefit after NICE approves ground-breaking CAR-T therapy to treat aggressive form of blood cancer – Catapult’s regulatory round-up
On the 26th of January 2023, NICE issued a final appraisal document recommending the treatment be made routinely available on the NHS for suitable patients.
People with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have had two or more lines of systemic therapy will now benefit from the first personalised immunotherapy treatment, Axicabtagene ciloleucel (Yescarta, Kite).
More information can be found here.
Published on the 3rd of March 2023 in Catapult’s regulatory round-up for february 2023.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (22 décembre 2023). More than 400 people set to benefit after NICE approves ground-breaking CAR-T therapy to treat aggressive form of blood cancer – Catapult’s regulatory round-up. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/vezc





